BMO Global Asset Management (Asia) Limited Announces ETF

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BMO Global Asset Management (Asia) Limited Announces ETF Dividends

HONG KONG, CHINA--(Marketwired - Oct. 19, 2016) - BMO Global Asset Management (Asia) Limited today announced dividends for its ETF line-up:

BMO ETF* Stock Code Cash Dividend per Unit (HK$)
BMO Asia USD Investment Grade Bond ETF 3141.HK 0.13
BMO Hong Kong Banks ETF 3143.HK 0.30
BMO Asia High Dividend ETF 3145.HK 0.17
BMO MSCI Asia Pacific Real Estate ETF 3121.HK 0.14
BMO MSCI Europe Quality Hedged to USD ETF 3165.HK 0.16
* BMO ETF is a Hong Kong umbrella unit trust authorized under section 104 of the Securities and Futures Ordinance (Cap 571) of Hong Kong.

The expected dividend date is October 27, 2016, and the record date is October 28, 2016. The distribution-payable date is November 8, 2016.

About BMO Global Asset Management

BMO Global Asset Management is a global investment manager with offices in more than 25 cities in 14 countries, delivering service excellence to clients across five continents.

Our four major investment centers in Toronto, Chicago, London and Hong Kong are complemented by a network of world-class boutique managers strategically located across the globe: BMO Real Estate Partners, LGM Investments, Monegy, Inc., Pyrford International Ltd., and Taplin, Canida & Habacht, LLC. BMO Global Asset Management is a signatory of the United Nations-supported Principles for Responsible Investment initiative (UNPRI).

BMO Global Asset Management is a part of BMO Financial Group, a highly diversified financial services provider based in North America with total assets of CDN $692 billion as of July 31, 2016, and over 45,000 employees. BMO Wealth Management has worldwide assets under management of CDN $402 billion.

IMPORTANT: BMO Asia USD Investment Grade Bond ETF, BMO Hong Kong Banks ETF, BMO Asia High Dividend ETF, BMO MSCI Asia Pacific Real Estate ETF and BMO MSCI Europe Quality Hedged to USD ETF (the "Sub-Funds") are established under BMO ETF, an umbrella unit trust. The Sub-Funds may not be suitable for all investors and investors should not invest based on this marketing material alone. Investors should read the BMO ETF prospectus (available at www.bmo.hk/etfs ) for further details, including product features and risk factors. ETFs are not guaranteed and past performance is not indicative of future performance. Investment involves risks. The value of investments and the income from them can go down as well as up, and investors may not get back the original amount invested.
• BMO Asia USD Investment Grade Bond ETF primarily invests in fixed rate USD-denominated government-related and corporate investment grade bonds of the Asia ex-Japan region. Such investments involve special risks including interest rate risk, over-the-counter market risk, issuer risk, sovereign debt risk and illiquidity of bonds close to maturity risk.
• BMO Hong Kong Banks ETF primarily invests in securities that are listed on The Stock Exchange of Hong Kong Limited and classified as Banks by the Industry Classification Benchmark (ICB). Stock prices of financial service companies are also more sensitive to the movement of interest rates.
• BMO Asia High Dividend ETF primarily invests in high dividend yield securities in Asia. Such securities are subject to risks that the dividend could be reduced or abolished, or the risks that the value of the securities could decline or have lower-than average potential for price appreciation.
• BMO MSCI Asia Pacific Real Estate ETF primarily invests in securities in the real estate sector in the Asia Pacific region, including real estate investment trusts (REITs). There are risks associated with the real estate sector and REITs in particular.
• BMO MSCI Europe Quality Hedged to USD ETF concentrates its investment in European securities.
• With respect to BMO Asia USD Investment Grade Bond ETF and BMO MSCI Asia Pacific Real Estate ETF, investing in emerging markets involves a greater risk of loss.
• BMO MSCI Europe Quality Hedged to USD ETF invests in currency forward contracts for hedging purposes and there are associated risks involved including costs of hedging, derivative and OTC transactions risks.
• The Sub-Funds are subject to concentration risk and tracking error risks, and may trade at a substantial premium or discount to their NAV.

DISCLAIMER: Nothing in this document is, or is intended to be, an offer, advice, or a solicitation to buy or sell any investments, and this document is directed only at persons in those jurisdictions where access to and use of such information is lawful. It is the responsibility of each investor to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Investors should seek the advice of professionals, as appropriate, regarding any particular investment. SFC authorization is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. This document is issued by BMO Global Asset Management (Asia) Limited, which is authorised and regulated in Hong Kong by the Securities and Futures Commission (the SFC). This advertisement has not been reviewed by the SFC.

®"BMO (M-bar roundel)" is a registered trade-mark of Bank of Montreal, used under licence.

Media Contacts: Yi Xie, Hong Kong +852 3716-0801 yi.xie@bmo.com Charlotte Bilney, Hong Kong +852 3103-0100 charlotte.bilney@citigate.com.hk
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles